Centus Biotherapeutics Limited   Report issue

For profit Phase 3
Founded: Cambridge United Kingdom (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2016
NCT02810457
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

bevacizumab (avastin) (1 trial)

carboplatin (paraplatin) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3